Successful therapy must eradicate cancer stem cells
Introduction
The human bone marrow is a site of very active cell proliferation to maintain homeostasis of circulating blood cells. The healthy bone marrow has considerable reserves for an acute increase in demand for cellular output in response to bleeding or infection. Normal cell turnover translates in the production of about 12 10 cells every day 1 . Cellular proliferation harbors the risk of acquiring mutations since the genome replication machinery is not perfect. Serial accumulation of mutations increases the probability of malignant transformation, especially if the mutations occur in long-lived cells 2 . The hierarchical structure of the hematopoietic system might have evolved in order to prevent the development of cancer: the long-lived stem cells divide rarely and only a small number of stem cells might actively contribute to hematopoiesis at any time 3, 4 . Such a tissue organization minimizes the risk of malignant transformation and is seen not only in the bone marrow, but also in epithelia with significant cell turnover 2, [5] [6] [7] .
Stem cells display several phenotypic characteristics that are considered critical for the acquisition of the tumor phenotype. These include the potential for unlimited cell replication, self-sufficiency and long-term survival 4, 8 . It is thus likely that many hematologic malignancies, such as myeloproliferative disorders and chronic myeloid leukemia (CML), originate from the hematopoietic stem cell compartment 9, 10 . There is increasing evidence that solid tumors also have a hierarchical structure with a small tumor stem cell compartment that maintains the growth of the rest of the tumor 4, 10, 11 . As compared to mature blood cells, stem cells are intrinsically less sensitive to the effects of chemotherapy due to a variety of mechanisms, including adhesion to the extracellular by on April 14, 2008 www.StemCells.com Downloaded from matrix and the production of membrane proteins that pump out many different chemotherapeutic agents [12] [13] [14] . Unfortunately, tumor stem cells similarly express these phenotypic characteristics. Tumor stem cell insensitivity to therapy may be a critical determinant of success or failure when a patient is treated.
Mathematical modeling of cancer was initiated in the 1950s [15] [16] [17] [18] and has led to considerable insights into the disease 5, 11, [19] [20] [21] [22] [23] . In the meanwhile, specific theories for cancer treatment and resistance have been studied [24] [25] [26] [27] [28] [29] [30] [31] . In this paper, we develop a quantitative understanding of the dynamics of cancer therapy. We design a simple mathematical model to study the response to treatment, and demonstrate the critical need for tumor stem cell eradication for successful therapy. Although the model is inspired by malignancies of the hematopoietic system 11 , it applies to all tumors that are maintained by tumor stem cells and provides significant insights into the treatment effects of diverse types of drugs.
The mathematical model
Our mathematical model considers two layers of the differentiation hierarchy of the hematopoietic system: stem cells have potential for indefinite self-renewal and give rise to differentiated cells which perform the functions of mature blood. Here we define differentiated cells as all cells that do not have stem cell characteristics. This hierarchy applies both to normal and tumor cells (Figure 1 Parameter estimates for the model are based on the observation that in a healthy adult, the numbers of hematopoietic stem cells and differentiated cells are around 2x10 4 We perform numerical simulations of equation (1) to investigate the impact of a therapeutic agent on the success of therapy. For the sake of clarity, therapeutic scenarios are assumed to change one parameter at a time. In the model, therapy decreases a given parameter linearly; for example, imatinib decreases the rate of production of progenitor and mature cells at least five thousand-fold 11 . We define cure as 1 0 < y cell, even though in practice, the tumor stem cell population perhaps need not die out for a cure to be operationally defined.
In order to test the sensitivity of the results to the input model parameters, we have studied the outcome of simulations where each parameter was varied by ±10%. All the results were robust across this range of values.
Results

Basic model characteristics.
In the absence of tumor cells, 0 ) ( ) ( Figure   2B ). In the absence of therapy, the tumor takes over and would ultimately drive the normal blood system to extinction.
Therapeutic scenarios
Cancer therapy can affect the mature cell compartment, the stem cell compartment, or both. The therapeutic effect may decrease the proliferation rate of tumor stem cells, increase their death rate, slow the rate of production of differentiated tumor cells, increase their death rate, and restore sensitivity to environmental cues of tumor stem cells. In the following, we explore the impact of therapy on these parameters in isolation or in combination in various therapeutic scenarios.
Therapy directed at mature tumor cells. Therapy that only increases apoptosis in the mature tumor cells (e.g. hydroxyurea and imatinib in CML) leads to an initial decrease in the tumor burden, but since the tumor stem cell pool continues to expand, therapy will ultimately fail due to the continuous amplification that occurs in the bone marrow ( Figure   2C ). Similarly, a therapeutic agent that decreases the rate at which mature tumor cells are generated (e.g. imatinib) cannot cure the disorder ( Figure 2D ). Therapy that both increases the death rate and suppresses generation of mature tumor cells will also fail for the same reason. If therapy is stopped, the mature tumor cells rapidly reappear and reach higher levels than those before initiation of therapy due to continuous expansion of the tumor stem cells ( Figure 2E ). This effect has been observed in some CML patients who stopped imatinib 11, 35 . Therefore, any treatment that is designed to eradicate the tumor must target the tumor stem cells.
Therapy directed at tumor stem cells.
A therapeutic agent designed to selectively inhibit the replication of tumor stem cells (e.g. interferon) can in principle lead to tumor eradication. In the best-case scenario, tumor stem cell proliferation is completely
, and the tumor stem cell pool decreases exponentially at a rate
. Such an agent, however, has to be continuously administered for a prolonged period to eradicate the tumor cell clone ( Figure 3A ). Since the presence of the tumor stem cell clone increases the risk of additional mutations and therefore more aggressive disease, the aim of therapy should be to eradicate the stem cell clone as rapidly as possible and minimize the risk of treatment failure 36 .
One of the characteristics of tumor cells is that they lose responsiveness to their surroundings. This effect is captured by the parameter y c in our model. We assume that the sensitivity to crowding of tumor stem cells is half that of the normal stem cells.
Therapy that only returns stem cell responsiveness to environmental cues to normal levels,
x y c c = , has very little impact on the time to tumor eradication (data not shown).
If this sensitivity is coupled with additional treatment effects, it can hasten treatment response.
Therapeutic agents may increase the death rate of the tumor stem cells. This effect can lead to relatively fast tumor eradication ( Figure 3B ). An agent that decreases the proliferation rate of the stem cell pool concomitantly can improve the outcome even further ( Figure 3C ). If the tumor stem cells die rapidly, the effect of sensitivity to the environment is not very important. Mutations leading to the evolution of resistance to therapy might also arise in progenitor cells. Therefore, an agent that can eliminate both tumor stem and mature cells quickly has the additional advantage that it minimizes the potential emergence of such resistance mutations ( Figure 3D ).
Side effects. Although targeted therapy is designed to eliminate toxicity to normal cells, complete absence of toxicity is rarely the case. Some side effects are observed with agents such as imatinib mesylate which can lead to neutropenia 37 . We therefore study the therapeutic outcome if a particular drug is only relatively selective to the tumor stem cells. If the selectivity of the drug is at least 1000 fold higher for tumor stem cells, then for practical purposes, its effect is almost identical to a drug with no side effects on normal stem cells. As the selectivity of the drug decreases, the normal stem cell pool is suppressed and therefore toxicity increases ( Figure 4A [38] [39] [40] [41] . This form of therapy is depicted in Figure 4B . In an ideal scenario, the therapeutic agent 'converts' the tumor stem cells to normal stem cells in all their characteristics. In such a case, therapy will not be able to eradicate the clone even if it is started early, but the patient will have normal and malignant hematopoiesis as long as the tumor stem cells remain sensitive to therapy. The acquisition of a resistance mutation will lead to rapid progression of the disease.
Finally, we study the effect of early and late initiation of therapy and the duration of treatment necessary for tumor stem cell eradication. Here we assume that the disease is diagnosed even before symptom development and in principle, this is possible with molecular diagnostics (e.g. Q-RT-PCR). Figure 4C shows the dependence of the time to cure on the start of therapy. Their relationship is non-linear with a lower tumor burden requiring a shorter period of therapy. However, once the tumor burden is large, the time required to cure the disease is independent of the burden and is determined by the death rate of the cells with therapy.
Discussion
In the last few years, our understanding of the molecular basis of hematopoietic neoplasms has expanded greatly. Molecular targets for CML 42 , acute promyelocytic leukemia (APL) 43 , hypereosinophilic syndrome/systemic mast cell disease 44 and a subtype of chronic myelomonocytic leukemia 45 can all be treated with imatinib mesylate or newer compounds designed to circumvent resistant mutants 46, 47 . It is only a matter of time before small molecule inhibitors for the JAKV617F mutation that has now been shown to be the cause of polycythemia vera will be identified 48 . These novel agents are associated with reduced toxicity, but they not only have to eliminate the hierarchy of tumor cells, but more importantly must destroy the malignant stem cell compartment 49 .
This is illustrated by observations in CML where withdrawal of imatinib therapy in patients who have been treated uninterruptedly for 3 years experience rapid relapse of the disease in the absence of mutations in the abl kinase 11, 35 . Similarly, differentiating agents that 'convert' tumor stem cells into normal stem cells cannot eradicate the tumor.
Although hematopoiesis may return to normal, cessation of therapy can lead to rapid relapse of the disease as has been observed in the initial studies of APL when ATRA was used alone 50 .
Mathematical modeling of hematopoiesis and the suppressive effects of chemotherapy and acquired tumor resistance have a long history 27, 28, [51] [52] [53] [54] [55] [56] . Often, multiple compartment models are invoked in order to explain the effects of chemotherapeutic agents on hematopoiesis 55 . In order to illustrate the importance of the malignant stem cell pool, we have developed a very simple compartment model of hematopoiesis where a small stem cell pool drives expansion of the rest of the tumor. In order to keep the mathematics simple, we chose to ignore the impact of feedback loops whereby the mature cell compartment exerts negative feedback on the stem cell pool. However, a model that includes such a feedback function does not give results that lead to significant differences from the conclusions derived from this simple model.
Therapy directed at the stem cell pool can stop tumor stem cell proliferation, induce apoptosis or return the cells' characteristics to those of normal stem cells. In the absence of mutations, a therapeutic agent that arrests tumor stem cell proliferation can lead to cure, but this requires prolonged therapy. While anti-mitotic therapy can in principle transform the tumor into a chronic disorder, this approach will not solve all problems.
One of the hallmarks of tumor cells is genetic instability which can lead to the acquisition of additional mutations and select for drug-resistant clones or biologically more aggressive disease 57 . Thus, rapid elimination of the tumor stem cell pool is an important goal and to reach it, agents that increase stem cell death have to be developed.
Furthermore, mutations causing resistance to therapy can also arise in mature tumor cells.
To minimize the risk of resistance of mature cells, effective therapeutic agents must quickly kill mature tumor cells as well as decrease the tumor stem cell load. Only such agents can eliminate the tumor rapidly and cure the disease before it progresses (Fig. 5 ).
It is also clear from these considerations that normalizing agents alone cannot provide satisfactory therapy of clonal hematological disorders.
Targeting the tumor stem cell is problematic, given the various mechanisms of resistance that these cells exhibit towards a wide variety of therapeutic agents. Some CML patients, 
